Lupin has recently received approval for a generic version of Oracea (Doxycycline Capsules) in the US market. The company has received approval for 40MG in the US, which is expected to have sales of $128 million in the US market. Lupin has a healthy pipeline of complex generic products in the US market which would aid the company in achieving quarterly US sales of $200-220 million.